natgillin/translations-raw huggingface dataset:
You should position the syringe in one hand with the needle pointing straight upwards as shown in Figure B. Put your thumb on the plunger rod and push slowly until you see a tiny liquid drop at the tip of the needle. 
Štrcaljku stavite u jednu ruku tako da je igla usmjerena ravno prema gore kako je prikazano na slici B.
How to store Kineret 
Moguće nuspojave Kako čuvati Kineret
0.67 ml of solution for injection in a graduated pre-filled syringe (Type I glass) with a plunger stopper (bromobutyl rubber) and 29 gauge needle. 
0,67 ml otopine za injekciju u kalibriranoj napunjenoj štrcaljki (staklo tipa I) sa čepom klipa
At the same time point, 7 of 12 in the Kineret treated group were classified as ACRpedi50 and 5 of 12 as ACRpedi70 responders compared to none in the placebo group. 
od 12 bolesnika kao bolesnici s odgovorom ACRpedi70 u usporedbi s nijednim bolesnikom u skupini koja je primala placebo.
Also persistent low-grade fever, weight loss, and persistent cough can be signs of an infection. 
Znakovi infekcije također mogu biti stalna blago povišena tjelesna temperatura, gubitak težine i uporan kašalj.
A corresponding decrease in creatinine clearance was seen in the hepatic failure population. 
Sukladno tome utvrđen je smanjeni klirens kreatinina u populaciji s dekompenzacijom jetre.
Kineret treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of RA, CAPS and Still's disease, respectively. 
4.2 Doziranje i način primjene Liječenje Kineretom treba započeti i nadzirati liječnik specijalist iskusan u dijagnosticiranju i liječenju
There may be some translucent-to-white particles of protein in the solution. 
U otopini mogu postojati neke prozirne do bijele čestice bjelančevina.
• a pre-filled syringe of Kineret 
• vanjski dio nadlaktica
Citric acid, anhydrous Sodium chloride Disodium edetate dihydrate Polysorbate 80 
6.1 Popis pomoćnih tvari citratna kiselina, bezvodna natrijev klorid dinatrijev edetat dihidrat polisorbat 80 natrijev hidroksid voda za injekcije
Patients with trisomy 21 seem to be overrepresented. 
Čini se da veći udio ovih bolesnika čine bolesnici s trisomijom 21. Nije ustanovljena uzročna povezanost s Kineretom.
Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. 
Kineret je indiciran u odraslih, adolescenata, djece i dojenčadi u dobi od 8 mjeseci i starije s tjelesnom težinom od najmanje 10 kg ili više za liječenje Stillove bolesti, uključujući sistemski juvenilni idiopatski artritis (engl.
- The other ingredients are anhydrous citric acid, sodium chloride, disodium edetate dihydrate, polysorbate 80 and sodium hydroxide and water for injections. 
- Drugi sastojci su bezvodna citratna kiselina, natrijev klorid, dinatrijev edetat dihidrat,
Immune system disorders 
Neonatal-Onset Multisystem Inflammatory
Your doctor will have to decide if you can still be given Kineret; - if you have a history of increased levels of liver enzymes; - if you require vaccinations. 
Liječnik će odlučiti da li još uvijek možete primati Kineret;
In clinical studies in RA patients, thrombocytopenia has been reported in 1.9% of treated patients compared to 0.3% in the placebo group. 
U kliničkim ispitivanjima u bolesnika s reumatoidnim artritisom trombocitopenija je prijavljena u 1,9%
Anakinra 
Chronic
Very common side effects (may affect more than 1 in 10 people): - Redness, swelling, bruising or itching at the injection site. 
- Svrbež kože ili osip Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba):
Malignancies 
Trombocitopenija
Kineret was studied in a single randomized, blinded multi-center trial in 86 patients with polyarticular course JIA (ages 2-17 years) receiving a dose of 1 mg/kg subcutaneously daily, up to a maximum dose of 100 mg. 
86 bolesnika s poliartikularnim JIA (dob 2-17 godina) koji su primali dozu od 1 mg/kg dnevno supkutanom injekcijom, do maksimalne doze od 100 mg. 50 bolesnika u kojih je postignut klinički odgovor nakon 12 tjedana otvorene, početne faze ispitivanja randomizirani su u skupine koje su daljnjih
This is a type of cytokine (an immunosuppressive agent) that is used to treat: - Rheumatoid Arthritis (RA) - Cryopyrin-Associated Periodic Syndromes (CAPS) which includes the following autoinflammatory diseases: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also called Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), - Muckle-Wells Syndrome (MWS), - Familial Cold Autoinflammatory Syndrome (FCAS) - Still´s disease including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD) 
Neonatal-Onset Multisystem Inflammatory Disease - NOMID) ili takozvani kronični infantilni neurološki, kutani i zglobni sindrom
Pull straight as shown in Figure A. Do not touch the needle or push the plunger. 
Nemojte dodirivati iglu ili gurati klip.
(~35 times the recommended dose in RA) over a 72 hour treatment period. 
U ispitivanjima sepse, 1015 bolesnika primilo je Kineret u dozama do 2 mg/kg/sat intravenski (~35 puta više od preporučene doze za bolesnike s RA) tijekom razdoblja liječenja od 72 sata.
The therapeutic response is primarily reflected by reduction in clinical symptoms such as fever, rash, joint pain, and headache, but also in inflammatory serum markers (CRP/SAA levels), or occurrence of flares. 
bol u zglobovima i glavobolja, ali i u razini upalnih markera u serumu (CRP/SAA razine) ili u ponovnom izbijanju bolesti.
The median steady-state dose-normalized anakinra concentration in SJIA patients over 28 weeks was comparable to that observed in RA patients. 
SJIA tijekom 28 tjedana bio je usporediv s onim uočenim u bolesnika s RA.
• Contact details of their physician 
• Kontakt podatke bolesnikova liječnika
In RA patients the most common and consistently reported treatment-related adverse reactions associated with Kineret were ISRs. 
Najčešće i dosljedno prijavljene nuspojave povezane s liječenjem Kineretom u bolesnika s RA bile su reakcije na mjestu primjene (engl.
Hearing and visual acuity did not deteriorate further during anakinra treatment. 
Tijekom liječenja anakinrom nije došlo do pogoršanja oštrine sluha i vida.
Hyperlink reference not valid.http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
The safety and efficacy have been demonstrated in a published randomized controlled study in 24 SJIA patients treated with Kineret for up to 1 year. 
Sigurnost i djelotvornost dokazane su u objavljenom randomiziranom kontroliranom ispitivanju u
Mechanism of action 
OKVIRA)
Breast-feeding 
Interleukin-1
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF 7 PRE-FILLED SYRINGES AS AN INTERMEDIATE PACK (WITHOUT BLUE BOX) 
ŠTRCALJKI KAO MEĐUPAKIRANJE (BEZ PLAVOG
SC 
Slika C
Two medicines are bioequivalent when they produce the same levels of the active substances in the body. 
Dva su lijeka bioekvivalentna ako u tijelu proizvode iste razine djelatne tvari.
There are no ongoing clinical trials or compassionate use programmes. 
Trenutačno nema kliničkih ispitivanja ili programa milosrdnog davanja su u tijeku.
In its letter notifying the Agency of the withdrawal of application, the company stated that the time required to generate the supporting data makes this product unviable. 
U dopisu kojim obavještava Agenciju o povlačenju zahtjeva tvrtka je navela da vrijeme koje je potrebno za prikupljanje popratnih podataka čini proizvod neodrživim.
The company informed the CHMP that this withdrawal has no consequences for patients. 
Tvrtka je obavijestila CHMP da nema posljedica za bolesnike zbog povlačenja.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the medicine could not have been approved based on the data presented by the company. 
U skladu s navedenim, u vrijeme povlačenja, CHMP je smatrao kako lijek nije moguće odobriti na temelju podataka koje je tvrtka dostavila.
It was expected to reduce the risk of fractures (broken bones) in the spine and the hip. 
Lijek je trebao smanjiti rizik od fraktura (prijeloma kostiju) kralješnice i kuka.
Alendronic acid reduces the loss of bone tissue and colecalciferol, also known as vitamin D3, increases the absorption of calcium and formation of bone. 
Alendronska kiselina smanjuje gubitak koštanog tkiva, a kolekalciferol, poznat i kao vitamin D3, povećava apsorpciju kalcija i formiranje kostiju.
On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. 
Dana 27. svibnja 2016. tvrtka Mylan SAS službeno je obavijestila Odbor za lijekove za humanu uporabu (CHMP) kako želi povući svoj zahtjev za odobrenje za stavljanje u promet lijeka Alendronska kiselina/kolekalciferol Mylan, za liječenje postmenopauzalne osteoporoze u žena s rizikom od nedostatka vitamina D.
This means that Alendronic Acid/Colecalciferol Mylan was intended to be similar to a ‘reference medicine' already authorised in the European Union called Fosavance. 
To znači da je lijek Alendronska kiselina/kolekalciferol Mylan trebao biti sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Fosavance.
Because Alendronic Acid/Colecalciferol Mylan is a generic medicine, the company had presented results of a study to determine that Alendronic Acid/Colecalciferol Mylan is bioequivalent to the reference medicine, Fosavance. 
Budući da je lijek Alendronska kiselina/kolekalciferol Mylan generički lijek, tvrtka je predstavila rezultate ispitivanja kako bi se utvrdilo da je lijek Alendronska kiselina/kolekalciferol Mylan bioekvivalentan referentnom lijeku Fosavance.
The CHMP also considered that data from the study do not convincingly establish that Alendronic Acid/Colecalciferol Mylan is sufficiently similar to the reference medicine, Fosavance. 
CHMP je također smatrao da na osnovi podataka iz ispitivanja nije uvjerljivo utvrđeno da je lijek Alendronska kiselina/kolekalciferol Mylan u dovoljnoj mjeri sličan referentnom lijeku Fosavance.
Alendronic Acid/Colecalciferol Mylan was to be used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of insufficient vitamin-D levels. 
Lijek Alendronska kiselina/kolekalciferol Mylan trebao se koristiti za liječenje osteoporoze (bolesti koja kosti čini lomljivima) u žena u postmenopauzi s rizikom od preniskih razina vitamina D.
Alendronic Acid/Colecalciferol Mylan was developed as a ‘generic medicine'. 
Lijek Alendronska kiselina/kolekalciferol Mylan razvijen je kao „generički lijek”.
Alendronic Acid/Colecalciferol Mylan is a medicine that contains two active substances: alendronic acid and colecalciferol. 
Alendronska kiselina/kolekalciferol Mylan lijek je koji sadrži dvije djelatne tvari, alendronsku kiselinu i kolekalciferol.
What is Alendronic Acid/Colecalciferol Mylan? 
Što je Alendronska kiselina/kolekalciferol Mylan?
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Alendronic Acid/Colecalciferol Mylan could not have been approved for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency. 
Na temelju pregleda podataka, u trenutku povlačenja CHMP je smatrao da postoje problemi te je njegovo privremeno mišljenje bilo da nije moguće dati odobrenje za lijek Alendronska kiselina/kolekalciferol Mylan za liječenje postmenopauzalne osteoporoze u žena s rizikom od nedostatka vitamina D. CHMP je izrazio zabrinutost zbog nesigurnosti u pogledu načina na koji je ispitivanje bioekvivalencije provedeno.
Alendronic Acid/Colecalciferol Mylan is expected to work in the same way as the reference medicine, Fosavance. 
Lijek Alendronska kiselina/kolekalciferol Mylan trebao je djelovati na isti način kao i referentni lijek, Fosavance.
How is Alendronic Acid/Colecalciferol Mylan expected to work? 
Kako je lijek Alendronska kiselina/kolekalciferol Mylan trebao djelovati?
What was Alendronic Acid/Colecalciferol Mylan expected to be used for? 
Za što se lijek Alendronska kiselina/kolekalciferol Mylan trebao koristiti?
What is Adlumiz? 
Što je Adlumiz?
15 September 2017 EMA/599030/2017 EMEA/H/C/003847 
EMA/599030/2017 EMEA/H/C/003847
It was to be available as 100 mg tablets to be taken by mouth. 
Trebao je biti dostupan u obliku tableta od 100 mg koje se uzimaju kroz usta.
Activation of the receptor causes release of substances in the body which are expected to act in the brain to increase appetite and prevent weight loss. 
Aktivacija receptora uzrokuje otpuštanje tvari u tijelu za koje se očekuje da će djelovanjem u mozgu povećati apetit i spriječiti gubitak tjelesne težine.
After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 14 September 2017. 
Nakon razmatranja razloga za ovaj zahtjev, CHMP je preispitao prvotno mišljenje i potvrdio odbijanje odobrenja za stavljanje lijeka u promet dana 14. rujna 2017.
In addition, following an inspection at clinical study sites, CHMP considered that the safety data on the medicine had not been recorded adequately. 
Osim toga, nakon inspekcije lokacija kliničkog ispitivanja, CHMP je smatrao da sigurnosni podatci o lijeku nisu zabilježeni na odgovarajući način.
This meant that a thorough evaluation of potential risks with Adlumiz was not possible. 
To je značilo da nije bila moguća detaljna procjena mogućih rizika lijeka Adlumiz.
Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride) EMA/599030/2017 
Odbijanje odobrenja za stavljanje u promet lijeka Adlumiz (anamorelin hidroklorid) EMA/599030/2017
The company that applied for authorisation is Helsinn Birex Pharmaceuticals Ltd. 
Zahtjev za izdavanje odobrenja podnijela je tvrtka Helsinn Birex Pharmaceuticals Ltd.
The company presented results of two main studies involving a total of around 1,000 non-small cell lung cancer patients with cachexia. 
Tvrtka je dostavila rezultate dvaju glavnih ispitivanja na ukupnom broju od otprilike 1000 bolesnika oboljelih od raka pluća nemalih stanica s kaheksijom.
Adlumiz is a medicine that contains the active substance anamorelin hydrochloride. 
Adlumiz je lijek koji sadržava djelatnu tvar anamorelin hidroklorid.
What was Adlumiz expected to be used for? 
Za što se lijek Adlumiz trebao koristiti?
How does Adlumiz work? 
Kako djeluje Adlumiz?
Therefore the CHMP was of the opinion that the benefits of Adlumiz did not outweigh its risks and recommended that it be refused marketing authorisation. 
Stoga je CHMP smatrao da koristi lijeka Adlumiz ne nadmašuju s njim povezane rizike te je preporučio odbijanje odobrenja za stavljanje lijeka u promet.
Patients were given either Adlumiz or placebo (a dummy treatment) and the main measures of effectiveness were changes in lean body mass (body weight excluding fat) and hand grip strength. 
Bolesnici su primili lijek Adlumiz ili placebo (prividno liječenje), a glavne mjere djelotvornosti bile su promjene bezmasne tjelesne mase (tjelesna težina bez masnog tkiva) i snage stiska šake.
The CHMP concluded that the studies show a marginal effect of Adlumiz on lean body mass and no proven effect on hand grip strength or patients' quality of life. 
CHMP je zaključio da su ispitivanja pokazala marginalan učinak lijeka Adlumiz na bezmasnu tjelesnu masu te da nije dokazan učinak na snagu stiska šake ni kvalitetu života bolesnika.
The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes in Europe with Adlumiz. 
Tvrtka je obavijestila CHMP da nema kliničkih ispitivanja ili programa milosrdnog davanja lijeka Adlumiz koji su u tijeku u Europskoj uniji.
Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride) 
Odbijanje odobrenja za stavljanje u promet lijeka Adlumiz (anamorelin hidroklorid)
Adlumiz was expected to be used to treat anorexia (loss of appetite), cachexia (a form of muscle wasting with significant weight loss) or unintended weight loss in patients with a type of lung cancer called non-small cell lung cancer. 
Lijek Adlumiz trebao se primjenjivati u liječenju anoreksije (gubitak apetita), kaheksije (oblik propadanja mišića popraćen znatnim gubitkom težine) ili neželjenog gubitka tjelesne težine u bolesnika oboljelih od vrste raka pluća naziva rak pluća nemalih stanica.
On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Adlumiz, intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer. 
Odbor za lijekove za humanu uporabu (CHMP) donio je negativno mišljenje i preporučio odbijanje odobrenja za stavljanje u promet lijeka Adlumiz, koji je namijenjen liječenju anoreksije, kaheksije ili neželjenog gubitka tjelesne težine u bolesnika s rakom pluća nemalih stanica.
Adlumiz attaches to and activates a target on cells called a ghrelin receptor. 
Lijek Adlumiz veže se na ciljne stanice i aktivira receptor za grelin.
7 ml (50 mg/ml) 1 vial 
350 mg koncentrat za otopinu za infuziju intravenska primjena bočica (staklo) 7 ml (50 mg/ml) 1 bočica
The full EPAR for Valdoxan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Valdoxan nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The recommended dose is one tablet once a day, taken at bedtime. 
Preporučena doza je jedna tableta jednom na dan, a uzima se neposredno prije spavanja.
Valdoxan might also help to normalise the patient's sleep patterns. 
Valdoxan može također pomoći pri normalizaciji režima spavanja bolesnika.
Valdoxan can only be obtained with a prescription and is available as tablets (25 mg). 
Valdoxan se izdaje samo na recept i dostupan je u obliku tableta (25 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Valdoxan on 19 February 2009. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Valdoxan na snazi u Europskoj uniji od 19. veljače 2009.
Valdoxan agomelatine 
Valdoxan agomelatin
Valdoxan is a medicine used to treat major depression in adults. 
Valdoxan je lijek koji se koristi za liječenje teške depresije u odraslih osoba.
However, the second study showed that symptoms returned in 21% of the patients taking Valdoxan over 24 weeks (34 out of 165), compared with 41% of the patients taking placebo (72 out of 174). 
No, drugo je ispitivanje pokazalo da su se simptomi vratili u 21 % bolesnika (34 od 165) koji su uzimali lijek Valdoxan tijekom 24 tjedna, u usporedbi s 41 % bolesnika (72 od 174) koji su uzimali placebo.
This is a summary of the European public assessment report (EPAR) for Valdoxan. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Valdoxan.
What is Valdoxan and what is it used for? 
Što je Valdoxan i za što se koristi?
What measures are being taken to ensure the safe and effective use of Valdoxan? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Valdoxan?
The company that markets Valdoxan will supply educational material for doctors prescribing Valdoxan. 
Tvrtka koja stavlja lijek Valdoxan u promet dostavit će edukacijski materijal liječnicima koji propisuju lijek Valdoxan.
Therefore, the CHMP decided that Valdoxan's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Stoga je CHMP odlučio da koristi od lijeka Valdoxan nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
However, since the medicine has a different mode of action, few side effects and a different safety profile to existing antidepressants, the Committee concluded that Valdoxan could be a valuable treatment for some patients as long as their liver function is tested frequently. 
No, s obzirom na to da lijek ima drugačiji način djelovanja, malobrojne nuspojave i drugačijeg je sigurnosnog profila u odnosu na postojeće antidepresive, Odbor je zaključio da lijek Valdoxan može biti vrijedna terapija za neke bolesnike sve dok se njihova funkcija jetre često kontrolira.
This material explains the safety of the medicine, its interactions with other medicines, and includes guidance on the monitoring of liver function and management of possible symptoms of liver problems. 
U tom se materijalu pojašnjava sigurnost lijeka, njegove interakcije s drugim lijekovima, a on obuhvaća i smjernice o praćenju funkcije jetre i kontroli eventualnih simptoma bolesti jetre.
In the first study, there was no difference between Valdoxan and placebo in preventing symptoms from returning during 26 weeks of treatment. 
U prvom ispitivanju nije bilo razlike između lijeka Valdoxan i placeba u sprječavanju vraćanja simptoma tijekom 26 tjedana liječenja.
Valdoxan has been compared with placebo (a dummy treatment) in five main short-term studies involving a total of 1,893 adults with major depression. 
Valdoxan je uspoređen s placebom (prividnim liječenjem) u pet glavnih kratkotrajnih ispitivanja kojima su bile obuhvaćene ukupno 1 893 odrasle osobe s teškom depresijom.
Other information about Valdoxan 
Ostale informacije o lijeku Valdoxan
In the two studies where no active comparator was used Valdoxan was seen to be more effective than placebo. 
U dvama ispitivanjima u kojima nije korišten aktivni komparator, Valdoxan se pokazao djelotvornijim od placeba.
It must also not be used in patients who are taking medicines that slow down the breakdown of Valdoxan in the body, such as fluvoxamine (another antidepressant) and ciprofloxacin (an antibiotic). 
Ne smije se koristiti niti u bolesnika koji uzimaju lijekove koji usporavaju razgradnju lijeka Valdoxan u tijelu, poput fluvoksamina (drugi antidepresiv) i ciprofloksacina (antibiotik).
In the other three studies, which did include an active comparator, there were no differences in scores between the patients taking Valdoxan and those taking placebo. 
U preostalim trima ispitivanjima, u kojima je korišten aktivni komparator, nije bilo razlika u rezultatima između bolesnika koji su uzimali Valdoxan i onih koji su uzimali placebo.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Valdoxan's benefits in terms of treating depression might be lower than seen with other antidepressants. 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji napomenuo je kako koristi lijeka Valdoxan u kontekstu liječenja depresije mogu biti manje od koristi uočenih s drugim antidepresivima.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Valdoxan have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Valdoxan nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
The active substance in Valdoxan, agomelatine, is an antidepressant. 
Djelatna tvar u lijeku Valdoxan, agomelatin, je antidepresiv.